Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term
- 20 May 2015
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (28) , 1794-1797
Abstract
This editorial refers to ‘Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease: the Loire Valley Atrial Fibrillation Project’, by R. Philippart et al., on page doi:10.1093/eurheartj/ehv163. A 76-year-old male patient with arterial hypertension and moderate aortic stenosis presents with the first episode of atrial fibrillation (AF). His CHA2DS2-VASC score is 3. Can we use the CHA2DS2-VASC score that has been developed in patients with non-valvular AF for assessment of his need for long-term oral anticoagulation? Also, since the underlying trials were done in patients with non-valvular AF, is this patient eligible for a non-vitamin K antagonist (NOAC) or does he have valvular disease and, thus, would need a vitamin K antagonist? These are frequently raised questions among cardiologists. Based on registry data, patients with AF and valve disease are common in clinical practice,1–6 with a higher proportion of these patients among those with permanent than those with paroxysmal or persistent AF1,2 ( Table 1 ). While the prevalence was reported as 21% in the Euro Heart Survey (defined as ‘any type of valve disease’)1 and 24.6% in AFNET (‘non-rheumatic valve disease’),2 it was only 4.2% in the PREvention oF thromboembolic events-European Registry in Atrial Fibrillation (PREFER in AF).6 The aim of the latter registry was to assess the management of AF in European countries after the publication of the 2010 European Society of Cardiology (ESC) Guidelines on AF which preferably addressed non-valvular AF. Thus, there may be a gap between the focus of the guidelines and the situation in clinical practice. View this table: Table 1 Composition of …Keywords
This publication has 15 references indexed in Scilit:
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive SummaryCirculation, 2014
- Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)EP Europace, 2013
- Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: Prospective non-interventional studyInternational Journal of Cardiology, 2013
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillationEuropean Heart Journal, 2012
- Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical PracticeCirculation: Arrhythmia and Electrophysiology, 2012
- Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registryClinical Research in Cardiology, 2011
- Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisionsThrombosis and Haemostasis, 2011
- The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial managementEP Europace, 2008
- ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm SocietyEP Europace, 2006
- Atrial fibrillation management: a prospective survey in ESC Member CountriesEuropean Heart Journal, 2005